Medicament for treatment of diarrhea

Abstract

Creosote has a novel pharmaceutical efficacy for treatment of various diseases with diarrhea. The medicament according to the present invention usually contains creosote, coptidis rhizoma, glycyrrhizae radix pulverata, cyperi rhizoma, auranti pericarpium and glycerinum, and it especially consists of 400 mg % of creosote, 200 mg % of coptidis rhizoma, 200 mg % of glycyrrhizae radix pulverata, 150 mg % of cyperi rhizoma, 200 mg % of auranti pericarpium and 100 mg % of glycerinum in each 9 pills.

Description

FIELD OF INVENTION

This invention relates to a novel usage of creosote as a medicament for treatment of diarrhea.

Creosote is a mixture of phenols and is obtained by the distillation of beechwood tar at about 200.degree.-220.degree.. Creosote consists of mainly phenol, cresol, guaiacol, xylenol and creosol. Creosote is a colorless or pale yellowish liquid and has a characteristic smoky odor and burning taste. This is hardly dissolved in water but is miscible with ethanol, ether, chloroform or soy-bean oil. Creosote has been recommended as a gastrointestinal antiseptic in the treatment of fermentative gastritis and enteritis and for its local anesthetic action upon the gastric mucosa in nausea and vomiting. And it has been also employed by dentists for obtunding sensitive dentine and as an ingredient of pastes for destruction of nerves. One or two drops of the pure substance are carefully introduced into the hollow of the tooth on a little cotton avoiding contact with the tongue or cheek.

However, it has never been known that creosote has other pharmaceutical efficacy than the above mentioned gastrointestinal antiseptic, etc.

SUMMARY OF INVENTION

Now we have found a novel pharmaceutical efficacy of creosote. Creosote has an outstanding pharmaceutical efficacy for treatment of various diseases with diarrhea, coupled with low toxicity.

Creosote is usally in form of pills, and pills may have sugar coat. And a medicament according to the present invention consists of creosote, coptidis rhizoma, glycyrrhizae radix pulverata, cyperi rhyzoma, auranti peric arpium and glycerinum.

DETAILED DESCRIPTION OF INVENTION

Acute toxicity tests of creosote in mice and rats are as follows:

(a) Test Material

Beechwood creosote used in the present tests was supplied by Perstorp Chemishe Werke (Perstorp, Sweden; lot. number 50623). A quantitative and qualitative analysis of this material by gaschromatography (Shimadzu, GC-4CMPE) is shown in TABLE 1.

TABLE 1______________________________________Analysis of the chemical components ofbeechwood creosote (Perstorp ChemischeWerke, Lot. NO. 50623) by gas chromatography Components %______________________________________1 phenol 12.842 o-cresol 8.693 m-cresol 11.71 p-cresol4 guaiacol 23.485 2,6-xyloenol 1.456 2,5-xylenol 6.367 3,5-xylenol 2.568 creosol 24.489 unknown 8.38Total 99.95______________________________________ (b) Experimental animals

Male and female ddY mice and Wistar rats were supplied from Shizuoka Agricultural Co. Assoc. for Laboratory Animals, and kept under observation for 1 week to establish their state of health. Powdered laboratory chaw (Oriental Yeast Co. Ltd., M) and water were available ad lib. The animals were randomly placed in wire-bottomed cages (3 mice and 2 or 3 rats per cage; CLEA Japan, CL-0206 and CL-239). Experiments were done in the isolated animal room which was automatically controlled under continuous ventilation and artificial lightening at 23.+-.2.degree. and 55.+-.5% relative humidity.

(c) Method

Aqueous solution of creosote (10%, v/v) was prepared by emulsifying creosote in water containing 33% of polyethylene glycol 400. The toxicity of PEG 400 at this concentration was negligible as determined by the concurrent control experiment. Female and male mice, weighing 20.+-.1 g in female and 21.+-.2 g in male, and rats weighing 78.+-.7 g in female and 98.+-.10 g in male, in groups of 10 animals each, were deprived of food overnight, and creosote solution was then administered orally using a stomach tube. The dose levels of creosote in mice and rats are given in TABLE 2. All animals were kept under observation for 7 days after creosote administration to elucidate the symptoms of poisoning and mortality of the animals. Single oral LD.sub.50 values were calculated by a formula of Litchfield-Wilconxon. The difference of mortality between female and male animals was compared statistically using Cochran's test.

TABLE 2__________________________________________________________________________Acute toxicity of creosote after an oral administration in mice and rats No. of No. of Dose animals dead Number of animals died withinAnimal Sex (mg/kg) examined animals 30 min 5 hr 24 hr 48 hr 7 days__________________________________________________________________________Mouse F 313 10 0 376 10 3 3 451 10 8 3 5 541 10 8 2 6 650 10 9 1 8 780 10 10 2 8 M 376 10 0 451 10 3 1 2 541 10 7 1 4 1 1 650 10 5 1 3 1 780 10 9 2 7 936 10 10 6 3 1Rat F 600 10 0 700 10 1 1 800 10 1 1 900 10 6 1 1 3 1 1000 10 9 1 1 7 1100 10 10 5 1 4 M 600 0 700 10 1 1 800 10 2 2 900 10 6 1 2 3 1000 10 8 1 1 5 1 1100 10 10 2 8__________________________________________________________________________ TABLE 3______________________________________Oral LD.sub.50 values of creosote in mice and rats LD.sub.50 95% confidence limitAnimal Sex (mg/kg) (mg/kg)______________________________________Mouse F 433 386-486 M 525 453-609Rat F 870 815-928 M 885 826-949______________________________________ (d) Results

The results of acute toxicity to single oral administration of creosote are shown in TABLE 2 and single oral LD.sub.50 values calculated from these data and 95% confidence limits of each value are shown in TABLE 3. The single oral LD.sub.50 values in mice were 433 mg/kg in female and 525 mg/kg in male, and those in rats were 870 mg/kg in female and 885 mg/kg in male. The mortality of female mice was significantly higher than that of male mice, while there was no significant difference between the mortality of female and male rats (Cochran's test with P<0.05).

The first sign of poisoning noted in mice and rats to which higher concentrations of creosote has been administered was a twitching of the muscles followed by a convulsion. The first twitching occured almost invariably in the extrinsic eye muscles and those of the eyelids and ears, then spread to isolated muscle bundles all over the body. These animals usually showed a marked convulsion 1 or 2 minutes after administration. Then, convulsion diminished gradually, giving way to a state of asphyxia and coma. Pulse and respiration were increased in the rate at first, but later become slow, irregular and weak. Most of these animals died within 30 minutes. The remaining animals gradually recovered, but several weakened animals died within 1 week after administration. Symptons of poisoning produced by lower concentrations of creosote resembled those described above, but on the whole convulsion was less severe, animals recovered more rapidly, and asphyxia or coma were observed on a small number of animals.

"Creosote Capsule" was administered to patients with various diseases who complained of diarrhea and efficacy of this therapy was evaluated on the basis of improvement of subjective and objective symptoms.

This drug was markedly effective for the improvement of abdominal pain, abdominal fullness, stool condition and frequency of defecation. In the evaluation of general efficacy, some efficacy was noted in all of the 148 patients. Namely, this drug was evaluated as markedly effective in 44, effective in 71 and sightly effective in 13.

Moreover, this drug was effective, regadless of sexes. When relationship between the rate of efficacy and age was examined, efficacy of "creosote" was noted in all age groups, though it was slightly higher in the younger generation. When relationship between various diseases with diarrhea and efficacy of "creosote" was examined, this drug was effective for all the patients with simple or habitual diarrhea and irritable or nervous diarrhea and about 70-80% of the patients with enterogastritis or acute enteritis.

On the other hand, the efficacy of this drug tended to be lower in chronic diseases. Accordingly, it is suggested that "creosote" may be an effective drug of the first choice for the treatment of moderate or mild diarrheal symptons which accompany relatively mild diseases and hardly induce, as basal diseases, organic disorderes of the digestive system. This implies wide range of application of "creosote" to diarrheal symptoms.

As side effects, each one patient with mild heartburn, mild nausea (mere irritation sympton), abdominal fullness and general redness (treatment was discontinued because of increased itching on the 2nd day) were noted (4 in total). However, since all of these symptons were mild and disappeared after short duration without any special treatment or discontinuance of medication, these were not regarded as definite adverse effects of this drug.

As described above, "creosote" has long been used by many people and it has been known to have high efficacy and usefulness and low incidence of adverse effects. On the basis of dosage and duration of treatment used in this study, it is expected that "creosote" may exert efficacy without any noticeable adverse effects.

Clinical trial with creosote in various diseases with diarrhea is as follows:

(a) Materials and Methods

(1) Patients and Diseases

This clinical trial was performed on the patients who were evaluated to be fitted for this purpose by their physicians on the basis of various laboratory data and other findings obtained during first visit.

(2) Age and Sex

The subjects of this study consisted of both male and female patients aged 15 to 85 years.

(3) Test material

Since single-taste oral administration of the test material was difficult because of its specific odor and taste, it was administered in a form of capsules with a vehicle (absorbent) to ensure accurate dosage.

______________________________________Drug form Contents of the constituents/capsule______________________________________Capsule J.P. Creosote 166 mg Metasilicic magnesium aluminate 66 mgDosage3 Capsules/day (t.i.d) after each mealDuration of treatment3 days as a rule______________________________________

During treatment with the test material, administration of other drugs such as creosote preparations, berbelic agents, antibiotics, synthetic antibacterials and intestinal drugs was avoided, if possible.

(a) Names of disease and No. of patients ______________________________________ No. of No. ofDiagnosis patients Diagnosis patients______________________________________Acute enteritis 71 Nervous diarrhea 3Acute enterogastritis 7 Enterogastritis 3Acute colitis 6 Nervous 1 enterogastritisChronic enterogastritis 2 Ulcerative colitis 3Chronic enteritis 6 Habitual diarrhea 1Chronic colitis 1 Catarrhal colitis 1Chronic diarrhea 1 Colitis 3Enterogastritis 14 Hemorrhagic gastriti 1due to coldSimple diarrhea 12 Gastric ulcer 1Irritable colitis 5 Acute pancreatitis 1Gastrogenic diarrhea 3 Suspected food 2 poisoningSubtotal Total______________________________________ (b) No. of patients of sexes Male: 71 Female: 77 (c) Age distribution ______________________________________No. of patientsAge (years) No. of patients______________________________________20 or younger 621-30 3031-40 2341-50 2251-60 3161 or older 36Total 148______________________________________ (d) Clinical course

Clinical course was observed for condition of stool, frequncy of defecation, abdominal pain, abdominal fullness, nausea, loss of strength, headache, dry mouth and body temperature.

(e) Clinical rating scale

Markedly effective: The patient feels fine because diarrhea has disappeared and the condition of stool improved markedly within 3 days of treatment.

Effective: The patient can live a daily life without significant difficulty because diarrhea and the condition of stool have improved and various other symptoms have been ameliorated to a large extent within 3 days of treatment. Slightly effective: Diarrhea, stool condition and various other symptons have been ameliorated slightly as compared with those before treatment within 3 days of treatment.

No Change: No improvement can be noted even after 4 days of treatment.

(b) Results

(1) Results of evaluation of general efficacy

When the effect of "creosote" on the patients with diarrhea was evaluated, the results were as shown in the following Table 4.

TABLE 4______________________________________Results of evaluation of general efficacyNo. and Rate No. Rate (%)______________________________________EfficacyMarkedly effective (++) 44 29.73Effective (+) 72 48.65Slightly effective (.+-.) 13 8.78No change (-) 19 12.84Total 148 100.00______________________________________

(2) Relationship between appearance of efficacy and sexes

When the presence of specific sex difference was examined in the improvement of diarrhea by the administration of "creosote", the results were as shown in Table 5. It is apparent from these table and figure that there is no specific sex difference in the improvement of diarrhea by "creosote".

TABLE 5______________________________________Relationship between appearance of efficacy and sexes Male FemaleSex, No. Rate No. Rate (%) No. Rate (%)______________________________________Markedly effective (++) 21 29.58 23 29.87Effective (+) 32 45.07 40 51.95Slightly effective (.+-.) 7 9.86 6 7.79No change (-) 11 15.49 8 10.39Total 71 100.00 77 100.00______________________________________

(3) Relationship between appearance and ages

Table 6 shows relationship between appearance of efficacy of "creosote" and ages.

According to this table, the rate of efficacy was highest in the age group of 21 30 years and no significant difference was noted among age groups other than the youngest one (20 or less). On the other hand, the rate of no change was highest (31.25%) in the group of 60 or more years and lowest in the group of 21 to 30 years, suggesting decrease in the rate of no change with decrease in age.

The rate of efficacy described above means the percentage of patients for whom this therapy was markedly effective or effective, and the rate of no change, the percentage of patients for whom it was slightly effective or uneffective.

TABLE 6__________________________________________________________________________Relationship between appearance of efficacy and agesDegrees and rates Markedly Slightlyof efficacy effective Effective effective No changeAge (years) No. % No. % No. % No. %__________________________________________________________________________20 or less 2 4.44 4 5.63 0 0 2 10.5321-30 12 26.67 15 21.13 0 0 3 15.7931-40 9 20.00 11 15.49 2 15.38 3 15.7941-50 6 13.33 12 16.90 0 0 5 26.3251-60 7 15.56 16 22.54 5 38.46 2 10.5361 or more 9 20.00 13 18.31 6 46.15 4 21.05Total 45 100.00 71 100.00 13 99.99 19 100.01__________________________________________________________________________

(4) Various diseases and appearance of efficacy

Table 7 shows relationship between various diseases with diarrhea studied and appearance of efficacy of "creosote" therapy. This table suggests that the rate of efficacy is high in acute enteritis, simple and habitual diarrhea, enterogastritis due to cold and enterogastritis and irritable and nervous diarrhea.

TABLE 5__________________________________________________________________________Efficacy on diarrhea in various diseases Markedly Slightly No effective Effective effective changeEvaluation (%) (++) (+) (+) (-) No. ofDiagnosis No. % No. % No. % No. % patients__________________________________________________________________________Acute enteritis 25 35.21 30 45.25 8 11.27 8 11.27 71Acute 1 14.29 5 71.43 0 0 1 14.29 7enterogastritisAcute colitis 1 16.67 5 83.33 0 0 0 0 6Chronic enteritis 0 0 3 50.00 2 33.33 1 16.67 6Chronic 0 0 0 0 1 50.00 1 50.00 2EnterogastritisChronic colitis 0 0 0 0 0 0 1 100.00 1Chronic diarrhea 0 0 1 100.00 0 0 0 0 1Enterogastritis 2 14.29 10 71.43 1 7.14 1 7.14 14due to coldSimple diarrhea 9 75.00 3 25.00 0 0 0 0 12Irritable 3 60.00 2 40.00 0 0 0 0 5colitisGastrogenic 0 0 3 100.00 0 0 0 0 3diarrheaNervous diarrhea 2 66.67 1 33.33 0 0 0 0 3Enterogastritis 1 33.33 1 33.33 0 0 1 33.33 3Nervous 0 0 1 100.00 0 0 0 0 1enterogastritisUlcerative colitis 0 0 2 66.67 0 0 1 33.33 3Habitual diarrhea 0 0 1 100.00 0 0 0 0 1Catarrhal colitis 0 0 1 100.00 0 0 0 0 1Colitis 0 0 1 33.33 0 0 2 66.67 3Hemorrhagic 0 0 0 0 0 0 1 100.00 1gastritisGastric ulcer 0 0 0 0 1 100.00 0 0 1Acute 0 0 1 100.00 0 0 0 0 1pancreatitisSuspected 0 0 1 50.00 0 0 1 50.00 2food poisoningTotal 44 72 13 19 148__________________________________________________________________________

(5) Drug administration and improvement of defecating frequency and stool condition

Administration of "creosote" resulted in the improvement of defecting frequency per day in the patients for whom this therapy was evaluated as markedly effective, effective or slightly effective. In addition, improvement of stool from mucus or watery to caddy, soft or normal was noted in all the patients for whom this therapy was evaluated as effective (markedly effective+effective) and in almost all the patients for whom it was evaluated as slightly effective.

(6) Side effects

As adverse effects probably due to this drug, each 1 case of abdominal fullness, mild nausea, mild heartburn and general redness (treatment was discontinued on the 2nd day of treatment because of increased itching) were noted (4 in total). These symptoms were mild and disappeared without any special treatment or discontinuance of administration in all but one.

EXAMPLE

A medicament consists of 400 mg% of creosote, 200 mg% of coptidis rhizoma, 200 mg% of glycyrrhizae radix pulverata, 150 mg% of cyperi rhizoma, 200 mg% of auranti pericarpium and 100 mg% of glycerinum in each 9 pills.

Claims

1. A diarrhea-treating medicament for treating various diseases with diarrhea comprising a diarrhea-treating effective amount of creosote and a pharamceutically acceptable carrier, wherein the medicament is contained in a capsule.